BioXcel Therapeutics (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced the initiation of the Phase 2 efficacy portion of the Phase 1b/2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) for treatment emergent Neuroendocrine Prostate Cancer (tNEPC). Initial interim data from this study is expected in the fourth quarter of 2020.

Enrollment of the pivotal SERENITY trials is progressing well, with topline data expected in mid-2020 The Company is assessing data for dose escalation in the.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an underwritten public offering of 2,000,000 shares of its common stock. In connection with the offering, BTI intends to grant the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock from BTI. To the extent the underwriters exercise their option to purchase additional shares of common stock, the Company intends to use the net proceeds from the sale of additional shares to repurchase shares of common stock (which shares will then be canceled) from BioXcel Corporation at a price equal to the price paid by the underwriters for such shares in the public offering.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced full enrollment of its pivotal Phase 3 SERENITY trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder. The Company expects to report topline data from both trials in July of 2020.

BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that more than one-third of the patients in the Phase 3 SERENITY trials have been enrolled and treated. To date, the company has not observed a change in enrollment rates resulting from the COVID-19 pandemic, and currently maintains previous guidance that SERENITY I & II are expected to be completed by mid-year 2020.

NEW HAVEN, Conn., March 02, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an underwritten public offering of 2,000,000 shares of common stock at a public offering price of $32.00 per share. In addition, BTI has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock from BTI at the public offering price, less underwriting discounts and commissions. Gross proceeds to BTI from the offering are expected to be approximately $64.0 million, before deducting underwriting discounts and commissions and offering expenses.

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT BioXcel Therapeutics, Inc. (NASDAQ:BTAI) currently has two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer

Landmine No. 1: Smaller biotech companies short on cash will face a funding crunch if the stock market stays down. How to diffuse it: Favor biotech companies that just raised cash, or have enough on hand to cover at least 18 months of cash burn, says Jefferies biotech analyst Michael Yee. Several companies were lucky enough to raise capital right before the biotech group started to fall apart on March 6.

NEW HAVEN, Conn., May 11, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT BioXcel Therapeutics, Inc. (NASDAQ:BTAI) currently has two lead development programs: BXCL501 – a sublingual formulation of the α2a adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of neurological and psychiatric disorders; and BXCL701 – an immuno-oncology agent for treatment of a rare form of prostate cancer

If you're interested in BioXcel Therapeutics, Inc. (NASDAQ:BTAI), then you might want to consider its beta (a measure...

NEW HAVEN, Conn., Feb. 26, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.

Good morning, everyone, and thank you for joining our conference call to discuss BioXcel Therapeutics' financial results and business highlights for the first-quarter 2020. Joining me for the call today are Richard Steinhart, chief financial officer; Frank Yocca, chief scientific officer; and Vince O'Neill, chief medical officer.

NEW HAVEN, Conn., May 05, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence.

NEW YORK, NY / ACCESSWIRE / March 9, 2020 / BioXcel Therapeutics, Inc. (BTAI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 9, 2020 at 8:30 AM ...

NEW HAVEN, Conn., May 07, 2020 -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial.

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update IND for Opioid Withdrawal Cleared by FDA On February 6, 2020, BioXcel (NASDAQ:BTAI) announced that the FDA has cleared the company’s IND for BXCL501 for the treatment of opioid withdrawal symptoms. The company will soon be initiating the Phase 1b/2 RELEASE trial, which will be a multicenter, randomized, double

Key BXCL501 data readouts expected in mid-2020 – including results from the SERENITY program and the Phase 1b/2 TRANQUILITY trial in geriatric dementia Strengthened balance.